Inge van Rooy
Impact in
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 5%
- Advanced Drug Delivery Systems
Papers in
-
- RNA Interference and Gene Delivery 4
- Glycosylation and Glycoproteins Research 2
- Advanced biosensing and bioanalysis techniques 1
-
- Nanoparticle-Based Drug Delivery 5
- Co-authors
- Raymond M. Schiffelers (7 shared papers)Gert Storm (7 shared papers)Enrico Mastrobattista (5 shared papers)Wim E. Hennink (5 shared papers)Zahi A. Fayad (2 shared papers)Willem J. M. Mulder (2 shared papers)Róbert Langer (1 shared paper)YongTae Kim (1 shared paper)
- Journals
- Pharmaceutical Research (2 papers)Expert Opinion on Biological Therapy (1 paper)International Journal of Pharmaceutics (1 paper)European Journal of Pharmaceutical Sciences (1 paper)Nanomedicine (1 paper)
- Partner nations
- NetherlandsUnited StatesNorway
In The Last Decade
Inge van Rooy
10 papers receiving 509 citations
Peers
Comparison fields: 5 of 74
- Biomaterials 260
- Pharmaceutical Science 70
- Neurology 46
- Molecular Biology 245
- Biomedical Engineering 156
Countries citing papers authored by Inge van Rooy
This map shows the geographic impact of Inge van Rooy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge van Rooy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge van Rooy more than expected).
Fields of papers citing papers by Inge van Rooy
This network shows the impact of papers produced by Inge van Rooy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge van Rooy. The network helps show where Inge van Rooy may publish in the future.
Co-authors
The 25 scholars most cited alongside Inge van Rooy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2010 | 155 | |
| 2 | 2010 | 103 | |
| 3 | 2013 | 86 | |
| 4 | 2013 | 59 | |
| 5 | 2010 | 58 | |
| 6 | 2011 | 22 | |
| 7 | 2007 | 12 | |
| 8 | 2020 | 12 | |
| 9 | 2005 | 11 | |
| 10 | 2011 | 2 |
About Inge van Rooy
Inge van Rooy is a scholar working on Molecular Biology, Biomaterials, Biomedical Engineering, Pharmaceutical Science and Radiology, Nuclear Medicine and Imaging, having authored 10 papers that have together received 520 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (5 papers), RNA Interference and Gene Delivery (4 papers), Nanoplatforms for cancer theranostics (2 papers), Advanced Drug Delivery Systems (2 papers), Glycosylation and Glycoproteins Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Advanced biosensing and bioanalysis techniques (1 paper) and MicroRNA in disease regulation (1 paper). The work is most often cited by research in Biomaterials (260 citations), Pharmaceutical Science (70 citations), Neurology (46 citations), Molecular Biology (245 citations) and Biomedical Engineering (156 citations). Inge van Rooy has collaborated with scholars based in Netherlands, United States and Norway. Frequent co-authors include Raymond M. Schiffelers, Gert Storm, Enrico Mastrobattista, Wim E. Hennink, Zahi A. Fayad, Willem J. M. Mulder, Róbert Langer, YongTae Kim, Anita Gianella and David P. Cormode. Their work appears in journals such as Pharmaceutical Research, Expert Opinion on Biological Therapy, International Journal of Pharmaceutics, European Journal of Pharmaceutical Sciences and Nanomedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.